Integrated Wealth Concepts LLC Has $6.06 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Integrated Wealth Concepts LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 3.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,256 shares of the medical research company’s stock after acquiring an additional 765 shares during the period. Integrated Wealth Concepts LLC’s holdings in Amgen were worth $6,061,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Capital World Investors lifted its holdings in shares of Amgen by 1,292.0% during the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock worth $1,693,042,000 after buying an additional 6,029,058 shares during the last quarter. Norges Bank acquired a new position in Amgen during the 4th quarter valued at $1,541,991,000. Capital International Investors boosted its holdings in Amgen by 40.1% in the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock valued at $3,182,843,000 after purchasing an additional 3,495,503 shares during the period. Charles Schwab Investment Management Inc. grew its position in Amgen by 25.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company’s stock worth $3,441,909,000 after purchasing an additional 2,672,975 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Amgen during the 4th quarter worth about $401,913,000. 76.50% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Bank of America raised their target price on Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research report on Wednesday, March 5th. Citigroup reiterated a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Morgan Stanley increased their price target on shares of Amgen from $328.00 to $330.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $324.00 price objective on shares of Amgen in a report on Friday, January 24th. Finally, StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus price target of $310.57.

Amgen Stock Up 0.4 %

Shares of NASDAQ AMGN opened at $280.84 on Friday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The firm has a market cap of $150.99 billion, a PE ratio of 37.20, a P/E/G ratio of 2.63 and a beta of 0.59. The company’s fifty day simple moving average is $301.52 and its 200 day simple moving average is $292.83.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.39%. Amgen’s payout ratio is 126.09%.

Insider Buying and Selling

In other news, EVP David M. Reese sold 8,711 shares of the stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total value of $2,554,239.42. Following the completion of the sale, the executive vice president now owns 62,147 shares in the company, valued at $18,222,743.34. This represents a 12.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.